Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), AstraZeneca plc (ADR) (NYSE:AZN), Merck & Co. (NYSE:MRK), Arena Pharmaceuticals (NASDAQ:ARNA)

Pfizer Inc. (NYSE:PFE)’s record of job cuts after acquisitions is now drawing heat from both sides of the Atlantic. U.S. and state politicians have joined their U.K. counterparts in questioning the economic impact of the drugmaker’s push to buy AstraZeneca Plc. (AZN). Pfizer Inc. (NYSE:PFE), net profit margin is 80.30% and weekly performance is -4.76%. On last trading day company shares ended up $29.03. Analysts mean target price for the company is $34.05. Pfizer Inc. (NYSE:PFE), distance from 50-day simple moving average (SMA50) is -6.64%.

On May 07, 2014, AstraZeneca plc (ADR) (NYSE:AZN), announced that it has once again rejected Pfizer, Inc.’s (PFE) offer to take over the company. The announcement came just a day after the American pharmaceutical giant attempted to lure the British drug maker with a $106 billion offer. AstraZeneca plc (ADR) (NYSE:AZN), shares fell 1.91% in last trading session and ended the day on $77.24. AZN, Gross Margin is 79.80% and its return on assets is 3.70%. AstraZeneca plc (ADR) (NYSE:AZN), quarterly performance is 24.62%.

Germany’s Bayer AG has trumped rival bidders for Merck & Co., Inc. (NYSE:MRK)’s consumer care business in a $14.2 billion (8.36 billion pounds) deal, adding to a string of major cross-border deals in the healthcare industry. Merck & Co., Inc. (NYSE:MRK), shares moved up 0.69% in last trading session and was closed at $55.21, while trading in range of $ 54.40 – 55.71. Merck & Co., Inc. (NYSE:MRK), year to date (YTD) performance is 11.18%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), reported that Eisai plans to add more than 200 new contract sales representatives to its Metabolic Business Unit, increasing the sales force for BELVIQ by 50% to approximately 600, triple the size from the commercial launch of BELVIQ in June 2013. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ended the last trading day at $7.19. Company weekly volatility is calculated as 4.74% and price to cash ratio as 7.10. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), showed a positive weekly performance of 7.63%.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *